Fig. 6
Doxorubicin chemoresistance is associated with the ABCB1 transporter. (A) Expression levels of ABCC1 in MDAN and MDAR cells under treatment with doxorubicin concentration range (0–1.6.6 µM) through qPCR determination; (B) under the same conditions, characterization of ABCB1 levels. In both cases, GAPDH was used as a reference gene, Results showed three biological replicates’ mean and standard deviation (n = 3, X ± S.D.). Molecular docking assay of ABCB1 (PDB: 7A69) under dox interaction, an increment in the interaction region is shown (C), and prediction of ABCB1 residues determinants of doxorubicin interaction obtained by MOE program (D). (E) Overlay of the ligand (doxorubicin) in its initial (green) and final (purple) conformations within the transmembrane binding pocket after a 10 ns molecular dynamics simulation. (F) RMSD of the ligand over the simulation time (10 ns), calculated with respect to the initial docking pose. (G) Overall survival plot for low and high expression of the ABCB1 gene in BC patients from GEPIA. (H) The overall survival plot for low and high expression of eIF4E in breast cancer patients was obtained from the GEPIA database (http://gepia2.cancer-pku.cn/#index). Data were statistically analyzed using one-way ANOVA and Newman–Keuls’s multiple comparison test **represents a p value < 0.01 and *** p-value < 0.001.
